| Title |
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, November 2019
|
| DOI | 10.2147/ceor.s215069 |
| Pubmed ID | |
| Authors |
Thitima Kongnakorn, Murtuza Bharmal, Mairead Kearney, Hemant Phatak, Agnes Benedict, Abhijeet Bhanegaonkar, Matthew Galsky |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 3 | 17% |
| Researcher | 3 | 17% |
| Student > Bachelor | 2 | 11% |
| Student > Master | 2 | 11% |
| Lecturer | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 6 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 22% |
| Business, Management and Accounting | 3 | 17% |
| Nursing and Health Professions | 2 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Veterinary Science and Veterinary Medicine | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 7 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2022.
All research outputs
#3,289,636
of 25,462,162 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#69
of 525 outputs
Outputs of similar age
#67,103
of 378,384 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#2
of 10 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,384 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.